MorphoSys AG has a consensus price target of $8.08 based on the ratings of 17 analysis. The 3 most-recent analyst ratings were released by Wells Fargo, Wells Fargo, and Wells Fargo on March 14, 2024, February 5, 2024, and December 15, 2023, respectively. With an average price target of $17.42 between Wells Fargo, Wells Fargo, and Wells Fargo, there's an implied -3.67% downside for MorphoSys AG from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
03/14/2024 | Buy Now | 0.94% | Wells Fargo | Derek Archila | $17 → $18.25 | Downgrade | Overweight → Equal-Weight | Get Alert |
02/05/2024 | Buy Now | -5.97% | Wells Fargo | Derek Archila | → $17 | Reiterates | Overweight → Overweight | Get Alert |
01/19/2024 | Buy Now | — | Morgan Stanley | James Quigley | — | Downgrade | Overweight → Equal-Weight | Get Alert |
01/16/2024 | Buy Now | — | Morgan Stanley | James Quigley | — | Downgrade | Overweight → Equal-Weight | Get Alert |
12/15/2023 | Buy Now | -5.97% | Wells Fargo | Derek Archila | $10 → $17 | Maintains | Overweight | Get Alert |
12/05/2023 | Buy Now | -52.99% | JP Morgan | Richard Vosser | $10 → $8.5 | Maintains | Overweight | Get Alert |
11/22/2023 | Buy Now | -73.73% | Goldman Sachs | Rajan Sharma | $9.25 → $4.75 | Maintains | Neutral | Get Alert |
11/21/2023 | Buy Now | -5.97% | JMP Securities | Jason Butler | → $17 | Reiterates | Market Outperform → Market Outperform | Get Alert |
10/13/2023 | Buy Now | -49.12% | Morgan Stanley | James Quigley | $3.7 → $9.2 | Upgrade | Underweight → Overweight | Get Alert |
09/15/2023 | Buy Now | -48.84% | Goldman Sachs | Rajan Sharma | $3.5 → $9.25 | Upgrade | Sell → Neutral | Get Alert |
06/22/2023 | Buy Now | -17.04% | JMP Securities | Jason Butler | → $15 | Reiterates | Market Outperform → Market Outperform | Get Alert |
06/16/2023 | Buy Now | -5.97% | Wells Fargo | Derek Archila | → $17 | Initiates | → Overweight | Get Alert |
06/16/2023 | Buy Now | -44.69% | JP Morgan | Richard Vosser | $3.3 → $10 | Upgrade | Underweight → Overweight | Get Alert |
01/03/2023 | Buy Now | — | JP Morgan | Richard Vosser | → $2.9 | Downgrade | Neutral → Underweight | Get Alert |
11/18/2022 | Buy Now | -17.04% | JMP Securities | Jason Butler | $32 → $15 | Maintains | Market Outperform | Get Alert |
01/14/2022 | Buy Now | — | Morgan Stanley | James Quigley | — | Downgrade | Overweight → Equal-Weight | Get Alert |
08/06/2021 | Buy Now | — | Deutsche Bank | — | — | Downgrade | Buy → Hold | Get Alert |
The latest price target for MorphoSys (NASDAQ:MOR) was reported by Wells Fargo on March 14, 2024. The analyst firm set a price target for $18.25 expecting MOR to fall to within 12 months (a possible -1.93% downside). 10 analyst firms have reported ratings in the last year.
The latest analyst rating for MorphoSys (NASDAQ:MOR) was provided by Wells Fargo, and MorphoSys downgraded their equal-weight rating.
The last upgrade for MorphoSys AG happened on October 13, 2023 when Morgan Stanley raised their price target to $9.2. Morgan Stanley previously had an underweight for MorphoSys AG.
The last downgrade for MorphoSys AG happened on March 14, 2024 when Wells Fargo changed their price target from $17 to $18.25 for MorphoSys AG.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of MorphoSys, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for MorphoSys was filed on March 14, 2024 so you should expect the next rating to be made available sometime around March 14, 2025.
While ratings are subjective and will change, the latest MorphoSys (MOR) rating was a downgraded with a price target of $17.00 to $18.25. The current price MorphoSys (MOR) is trading at is $18.61, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.